Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.48 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | DRD5 | P21918 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1904920 | 0.85 | SLC7A5 (0.49) | CYP1A2CTBP2 | |
| SCHEMBL3414264 | 0.84 | RXRA (0.49) | AKR1B1PPARDFFAR1 | |
| SCHEMBL29385263 | 0.84 | CA5A (0.54) | PTGDR2AKR1B1PPARDFFAR1CYP1A2 | |
| SCHEMBL25215347 | 0.84 | CA5A (0.54) | PTGDR2AKR1B1PPARDFFAR1CYP1A2 | |
| SCHEMBL9710054 | 0.83 | F10 (0.46) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL5123961 | 0.83 | ALDH1A1 (0.56) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL6937296 | 0.83 | CYP4F2 (0.55) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL8499667 | 0.81 | DRD2 (0.46) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL4652343 | 0.81 | DRD2 (0.47) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL761677 | 0.81 | MAPK14 (0.54) | FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629366-B2 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-08 | — | — | US | disclosed |
| US-20060100252-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-11 | — | — | US | disclosed |
| US-7037938-B2 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2006-05-02 | — | — | US | disclosed |
| EP-1546086-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-29 | — | — | EP | disclosed |
| US-20040006143-A1 | For therapy of urinary incontinence | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-01-08 | — | — | US | disclosed |
| WO-2004002939-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100252-A1 | Aminoalcohol derivatives | H1-0, CHRM2, CHRM1 | PTGDR2 459/4885AKR1B1 277/4885PPARD 1309/4885 |
| US-20040006143-A1 | For therapy of urinary incontinence | H1-0, HRH2, H1-2 | PTGDR2 938/4885AKR1B1 997/4885PPARD 2734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.